PharmaNutra SpAFRA:761 +1.62%96 EV-to-FCF is 52.88 as of Jul. 07, 2026, which is 54% above its 10-year median of 34.40. GuruFocus rates FRA:761 with a GF Score™ of 96/100 and a GF Value™ of €68.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 563 Drug Manufacturers companies, PharmaNutra SpA ranks worse than 75.31% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PharmaNutra SpA's Enterprise Value is €847.0 Mil.
PharmaNutra SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €16.0 Mil. Therefore, PharmaNutra SpA's EV-to-FCF for today is 52.88.
The historical rank and industry rank for PharmaNutra SpA's EV-to-FCF or its related term are showing as below:
FRA:761'
s EV-to-FCF Range Over the Past 10 Years
Min: -526.28 Med: 34.4 Max: 357.21
Current: 52.7
During the past 11 years, the highest EV-to-FCF of PharmaNutra SpA was 357.21. The lowest was -526.28. And the median was 34.40.
FRA:761's EV-to-FCF is ranked worse than 75.31% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs FRA:761: 52.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaNutra SpA's PE Ratio (TTM) for today is calculated as:
PharmaNutra SpA's share price for today is €87.90.
PharmaNutra SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PharmaNutra SpA EV-to-FCF Related Terms
PharmaNutra SpA EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's EV-to-FCF falls into.
PharmaNutra SpA's current Enterprise Value is €847.0 Mil.
PharmaNutra SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaNutra SpA (FRA:761) has a EV-to-FCF of 52.88 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmaNutra SpA and its competitors. This is 54% above median its historical median of 34.40. According to the industry distribution chart, PharmaNutra SpA ranks #424 out of 563 companies in the Drug Manufacturers industry, placing it in the top 75.3%.
Is PharmaNutra SpA's EV-to-FCF too high?
PharmaNutra SpA's current EV-to-FCF of 52.88 is 54% above median its 10-year median of 34.40. The Drug Manufacturers industry median EV-to-FCF is 20.85. PharmaNutra SpA's value of 52.88 is 153.6% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #424 out of 563 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PharmaNutra SpA has a GF Score™ of 96/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #424 out of 563 companies for EV-to-FCF. This places PharmaNutra SpA in the lower half of its industry. The industry median EV-to-FCF is 20.85. PharmaNutra SpA's value of 52.88 is 153.6% above this benchmark. While the company's 10-year median is 34.40 vs. the industry median of 20.85, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current EV-to-FCF of 52.88 is 153.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmaNutra SpA and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current EV-to-FCF is 52.88, which is 54% above median its own 10-year median of 34.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (FRA:761) is currently considered Modestly Overvalued. The stock's GF Value™ is €68.24, compared to a current price of €87.90 — trading 28.8% above its estimated fair value. The current EV-to-FCF is 52.88, which is 54% above median its 10-year median of 34.40 and 153.6% above the Drug Manufacturers industry median of 20.85. PharmaNutra SpA's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PharmaNutra SpA (FRA:761), the current EV-to-FCF is 52.88 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (FRA:761) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €87.90 is trading 28.8% above its estimated GF Value™ of €68.24.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for FRA:761:
EV-to-FCF: 52.88 (54% above median its 10-year median of 34.40)
GF Value™: €68.24 vs. price of €87.90 (28.8% above fair value)
Industry Position: 153.6% above the Drug Manufacturers median (#424 of 563)
No single metric tells the full story. See the FRA:761 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
96GF Score
Get the complete analysis for FRA:761
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:761 has been successfully added to your 
